A side effect observed during preclinical studies of a potential heart drug is underpinning the development of a peptide that shows promise in restoring hair growth. Follicum AB CBO Gunnar Gårdemyr took time out during his busy partnering schedule at BIO-Europe Spring 2018 to update Scrip on the progress the company is making with FOL-005, which is currently in Phase I/II studies and available for out-licensing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?